Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.63 |
| ▸ | GCK | P35557 | 10/20 | 0.49 |
| ▸ | PTGDR | Q13258 | 6/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2668907 | 0.88 | KCNH2 (0.63) | KCNH2GCKMEN1KMT2A | |
| SCHEMBL1171463 | 0.88 | KCNH2 (0.63) | KCNH2GCKPTGDRTBXA2RMEN1 | |
| SCHEMBL1445384 | 0.88 | KCNH2 (0.63) | KCNH2GCKPTGDRTBXA2RMEN1 | |
| SCHEMBL1445381 | 0.88 | KCNH2 (0.63) | KCNH2GCKPTGDRTBXA2RMEN1 | |
| SCHEMBL1171465 | 0.88 | KCNH2 (0.63) | KCNH2GCKPTGDRTBXA2RMEN1 | |
| SCHEMBL2650827 | 0.87 | KCNH2 (0.62) | KCNH2GCKMEN1KMT2A | |
| SCHEMBL2647926 | 0.87 | KCNH2 (0.62) | KCNH2GCKMEN1KMT2A | |
| SCHEMBL1171349 | 0.87 | KCNH2 (0.62) | KCNH2GCKPTGDRTBXA2RMEN1 | |
| SCHEMBL1171354 | 0.87 | KCNH2 (0.62) | KCNH2GCKPTGDRTBXA2RMEN1 | |
| SCHEMBL1171353 | 0.87 | KCNH2 (0.62) | KCNH2GCKPTGDRTBXA2RMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
| US-8153677-B2 | Substituted pyrazolylamide compounds useful as glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110118211-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-19 | — | — | US | disclosed |
| US-7910747-B2 | Phosphonate and phosphinate pyrazolylamide glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-22 | — | — | US | disclosed |
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118211-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, MPO, GCK | KCNH2 921/4885GCK 3/4885PTGDR 3014/4885 |
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | KCNH2 716/4885GCK 2/4885PTGDR 2391/4885 |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | KCNH2 634/4885GCK 2/4885PTGDR 2766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.